Andreas von Deimling

Q: What Schools Are Affiliated With Andreas von Deimling

Andreas von Deimling is affiliated with the following schools: Technical University of Munich, Heidelberg University

Andreas von Deimling's AcademicInfluence.com Rankings

Biology

#7332

World Rank

#10235

Historical Rank

Molecular Biology

#837

World Rank

#858

Historical Rank

Neuroscience

#935

World Rank

#974

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Andreas von Deimling Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Andreas von Deimling's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. (2021) (2388)
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (2015) (2211)
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. (2012) (1532)
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. (2003) (952)
Long-term survival with glioblastoma multiforme. (2007) (812)
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. (2015) (782)
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. (2009) (779)
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas (2012) (766)
The whole-genome landscape of medulloblastoma subtypes (2017) (658)
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. (2014) (601)
Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. (2013) (575)
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. (2009) (561)
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. (2012) (549)
Lomustine and Bevacizumab in Progressive Glioblastoma (2017) (540)
EANO guidelines for the diagnosis and treatment of meningiomas. (2016) (524)
International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading (2014) (514)
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020) (486)
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors (2010) (478)
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
Guidelines on management of low‐grade gliomas: report of an EFNS–EANO * Task Force (2010) (453)
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. (2017) (447)
CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. (1996) (442)
Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. (2011) (437)
Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. (1997) (397)
Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. (2016) (374)
Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. (2020) (367)
Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma (1995) (359)
Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency. (2002) (350)
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (2016) (342)
Histone Deacetylase 8 in Neuroblastoma Tumorigenesis (2009) (333)
A new clinico-pathological classification system for mesial temporal sclerosis (2007) (330)
p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. (1992) (320)
Yes and PI3K bind CD95 to signal invasion of glioblastoma. (2008) (315)
Post-mortem studies in glioblastoma patients treated with thermotherapy using magnetic nanoparticles. (2009) (301)
cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading (2020) (293)
Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma (2013) (286)
Inositol-requiring enzyme 1α is a key regulator of angiogenesis and invasion in malignant glioma (2010) (280)
Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-β (2011) (266)
Analysis of the neurofibromatosis 2 gene reveals molecular variants of meningioma. (1995) (266)
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (2018) (264)
TERT Promoter Mutations and Risk of Recurrence in Meningioma. (2016) (259)
Molecular pathways in the formation of gliomas (1995) (245)
Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. (1996) (241)
Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. (2016) (237)
Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. (1992) (233)
Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience (2018) (232)
Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. (1992) (232)
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR (2014) (227)
Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. (2011) (226)
The retinoblastoma gene is involved in malignant progression of astrocytomas (1994) (226)
Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression. (1995) (223)
Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. (2016) (221)
Central neurocytoma: histopathological variants and therapeutic approaches. (1992) (220)
The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants (2016) (220)
Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. (2019) (216)
Adult medulloblastoma comprises three major molecular variants. (2011) (215)
Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. (1999) (212)
Impact of Genotype and Morphology on the Prognosis of Glioblastoma (2002) (209)
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation (2013) (204)
BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. (2012) (203)
Targeting the BRAF V600E mutation in multiple myeloma. (2013) (202)
Molecular staging of intracranial ependymoma in children and adults. (2010) (192)
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
Expression and distribution of vascular endothelial growth factor protein in human brain tumors (1997) (186)
Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. (2015) (183)
The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations (2011) (180)
Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma (2012) (180)
Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses (1998) (177)
Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. (2002) (172)
Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic? (2011) (171)
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial (2017) (170)
HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth (2010) (167)
Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors (2000) (166)
Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity (2013) (165)
Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. (2000) (162)
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells (2011) (162)
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma (2016) (160)
Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing. (2013) (159)
Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. (1994) (153)
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations (2013) (152)
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. (2011) (152)
Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma (2018) (149)
Sarcoma classification by DNA methylation profiling (2021) (147)
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma (2013) (146)
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy (2013) (141)
Histogenesis and differentiation potential of central neurocytomas. (1991) (141)
Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. (2019) (138)
Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma (2013) (138)
Accumulation of wild type p53 protein in human astrocytomas. (1993) (137)
A vaccine targeting mutant IDH1 in newly diagnosed glioma (2021) (137)
Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. (2006) (134)
Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat (2001) (132)
Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker? (2007) (130)
Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation (2015) (130)
Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles (2016) (129)
Application of a BRAF V600E Mutation-specific Antibody for the Diagnosis of Hairy Cell Leukemia (2012) (128)
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. (2019) (128)
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. (2019) (128)
Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. (2012) (127)
Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. (2009) (126)
Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma (2012) (123)
Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer. (1996) (122)
The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. (2013) (122)
Effects of barium on stimulus‐induced rises of [K+]o in human epileptic non‐sclerotic and sclerotic hippocampal area CA1 (2000) (121)
Addressing diffuse glioma as a systemic brain disease with single-cell analysis. (2012) (119)
BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome (2013) (118)
Molecular characterization of long‐term survivors of glioblastoma using genome‐ and transcriptome‐wide profiling (2014) (117)
Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes (2010) (115)
Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. (2020) (115)
Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. (2013) (114)
Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors (2017) (114)
BRAF V600E‐specific immunohistochemistry for the exclusion of Lynch syndrome in MSI‐H colorectal cancer (2013) (113)
Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. (1994) (112)
Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling (2012) (112)
Patterns of differentiation in central neurocytoma. An immunohistochemical study of eleven biopsies. (1990) (110)
TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. (2010) (107)
Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors (2004) (106)
A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma (2014) (106)
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? (2011) (103)
LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR) (2012) (103)
BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease (2014) (102)
A (CA)n dinucleotide repeat assay for evaluating loss of allelic heterozygosity in small and archival human brain tumor specimens. (1992) (102)
Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features (2018) (101)
Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. (2010) (101)
Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. (1999) (101)
MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. (1994) (100)
Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions (2013) (100)
Loci associated with malignant progression in astrocytomas: a candidate on chromosome 19q. (1994) (100)
Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-alpha pathway in human astrocytic gliomas. (1996) (98)
Molecular genetic analysis of giant cell glioblastomas. (1997) (96)
Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. (2009) (95)
Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence (2018) (94)
Deletion mapping of chromosome 19 in human gliomas (1994) (93)
Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval. (1996) (93)
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas (2020) (92)
Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. (2006) (91)
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo (2017) (91)
Tweety-Homolog 1 Drives Brain Colonization of Gliomas (2017) (90)
The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin (2008) (90)
Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation‐induced human meningiomas (2001) (89)
Molecular signatures classify astrocytic gliomas by IDH1 mutation status (2011) (89)
Targeted genomic profiling of acral melanoma. (2019) (89)
Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations (2018) (88)
Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. (2000) (88)
Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis (2018) (87)
Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia. (2013) (87)
Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery (2017) (85)
The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis (2012) (85)
Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre (2019) (84)
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. (2013) (83)
Combined BRAFV600E-positive Melanocytic Lesions With Large Epithelioid Cells Lacking BAP1 Expression and Conventional Nevomelanocytes (2013) (82)
The putative glioma tumor suppressor gene on chromosome 19q maps between APOC2 and HRC. (1994) (82)
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. (2016) (81)
Analysis of the RET,GDNF, EDN3, andEDNRB genes in patients with intestinal neuronal dysplasia and Hirschsprung disease (2001) (79)
N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. (2018) (79)
Evaluation of Microvascular Permeability with Dynamic Contrast-Enhanced MRI for the Differentiation of Primary CNS Lymphoma and Glioblastoma: Radiologic-Pathologic Correlation (2014) (78)
Diagnostic challenges in meningioma. (2017) (77)
Mutational analysis of TSC1 and TSC2 genes in gangliogliomas (2001) (77)
CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas (2020) (77)
Identification of novel oligodendroglioma‐associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray‐based expression profiling (2006) (76)
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. (2008) (75)
Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. (2014) (75)
Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme (1996) (74)
Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival (2010) (74)
Evidence of H3 K27M mutations in posterior fossa ependymomas (2016) (73)
Carbon ion radiation therapy for high-risk meningiomas. (2010) (70)
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities (2014) (70)
MYCN amplification drives an aggressive form of spinal ependymoma (2019) (70)
The Molecular Landscape of ETMR at Diagnosis and Relapse (2019) (70)
Desmoplastic cerebral astrocytomas of infancy: a histopathologic, immunohistochemical, ultrastructural, and molecular genetic study. (1992) (70)
Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. (2014) (69)
Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. (1999) (69)
Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information (2018) (68)
Incidence, mortality and outcome of meningiomas: A population-based study from Germany. (2019) (68)
D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma (2014) (68)
IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT (2019) (67)
Molecular and translational advances in meningiomas. (2019) (67)
K27M-mutant histone-3 as a novel target for glioma immunotherapy (2017) (67)
Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. (2010) (67)
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas (2021) (67)
Malignant transformation of a gangliocytoma/ganglioglioma into a glioblastoma multiforme: a molecular genetic analysis. Case report. (2001) (65)
Scientific Correspondence (2011) (65)
Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data (2020) (65)
Subtyping of oligo‐astrocytic tumours by comparative genomic hybridization (2001) (65)
Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. (2005) (65)
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033 (2018) (64)
Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. (2014) (64)
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma (2015) (64)
Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR (2008) (64)
Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course (2019) (64)
Improved correlation of the neuropathologic classification according to adapted world health organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas. (2011) (63)
Ligands for PPARγ and RAR Cause Induction of Growth Inhibition and Apoptosis in Human Glioblastomas (2003) (63)
cIMPACT‐NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification (2017) (62)
Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. (2010) (62)
Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas (2017) (61)
PCR‐ and Restriction Endonuclease‐Based Detection of IDH1 Mutations (2010) (60)
The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. (1996) (60)
Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial (2018) (60)
Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. (1995) (59)
Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1 (2001) (58)
Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. (2012) (58)
Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation (2000) (58)
Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. (2007) (57)
Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. (2014) (57)
High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. (2014) (57)
Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma (2020) (57)
Glioma IDH1 mutation patterns off the beaten track. (2011) (56)
Epigenetic Silencing of Death Receptor 4 Mediates Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Resistance in Gliomas (2009) (56)
Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. (2017) (56)
DNA hypermethylation and Aberrant Expression of the EMP3 Gene at 19q13.3 in Human Gliomas (2007) (55)
A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. (2020) (55)
Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG (2013) (55)
Integrated molecular characterization of IDH‐mutant glioblastomas (2018) (55)
Molecular Genetic Analysis of Oligodendroglial Tumors (2005) (55)
ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. (2013) (55)
Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. (2013) (55)
CIC protein instability contributes to tumorigenesis in glioblastoma (2019) (54)
Detection of 2‐Hydroxyglutarate in Formalin‐Fixed Paraffin‐Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry (2012) (53)
Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas (2011) (53)
Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. (2005) (53)
cIMPACT‐NOW: a practical summary of diagnostic points from Round 1 updates (2019) (53)
Mutational patterns and regulatory networks in epigenetic subgroups of meningioma (2019) (52)
Aberrant self‐renewal and quiescence contribute to the aggressiveness of glioblastoma (2014) (52)
Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues (2014) (52)
Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. (2009) (51)
Identification of diagnostic serum protein profiles of glioblastoma patients (2010) (51)
Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated (2021) (51)
A device for processing large acrylamide gels. (1994) (51)
RASSF1A, BLU, NORE1A, PTEN and MGMT Expression and Promoter Methylation in Gliomas and Glioma Cell Lines and Evidence of Deregulated Expression of de novo DNMTs (2009) (51)
Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event (2012) (50)
Chromosome 19q Deletions in Human Gliomas Overlap Telomeric to D19S219 and May Target a 425 kb Region Centromeric to D19S112 (1995) (50)
Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis (2018) (49)
Hereditary tumor syndromes and gliomas. (2009) (49)
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets (2021) (49)
GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. (2014) (49)
The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial. (1995) (48)
TP53 Gene Mutations, Nuclear p53 Accumulation, Expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) Proteins are not Prognostic Factors in De Novo Glioblastoma Multiforme (2001) (48)
Survival According to BRAF-V600 Tumor Mutations – An Analysis of 437 Patients with Primary Melanoma (2014) (47)
The SRCR/SID region of DMBT1 defines a complex multi‐allele system representing the major basis for its variability in cancer (2002) (47)
Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. (2012) (47)
Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. (2007) (47)
Characterization of the human Rad51 genomic locus and examination of tumors with 15q14-15 loss of heterozygosity (LOH). (1999) (46)
Suppression of TDO‐mediated tryptophan catabolism in glioblastoma cells by a steroid‐responsive FKBP52‐dependent pathway (2015) (46)
Prognostic but not predictive role of platelet‐derived growth factor receptors in patients with recurrent glioblastoma (2011) (46)
Nestin Expression Identifies Ependymoma Patients with Poor Outcome (2012) (45)
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma (2015) (45)
Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. (2018) (45)
Primary T-cell lymphoma of the central nervous system. (1990) (45)
Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1 (2019) (45)
Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. (2016) (45)
A role for beta-melanocyte-stimulating hormone in human body-weight regulation. (2006) (45)
Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. (2012) (45)
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation (2018) (44)
Expression of the ATM gene is significantly reduced in sporadic breast carcinomas (1998) (44)
Impaired Pten Expression in Human Malignant Peripheral Nerve Sheath Tumours (2012) (44)
Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase (2012) (44)
PROX1 is a predictor of survival for gliomas WHO grade II (2011) (43)
Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype (2019) (43)
The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms - results of an ablate and resect study. (2011) (43)
DNA methylation-based reclassification of olfactory neuroblastoma (2018) (43)
Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours (2000) (43)
The p53 Tumor Suppressor Is Stabilized by Inhibitor of Growth 1 (ING1) by Blocking Polyubiquitination (2011) (42)
Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases (2017) (42)
A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1 (2013) (42)
DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment (2018) (42)
DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1–NFATc2 fusion from Ewing sarcoma (2019) (42)
Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. (2020) (41)
Loss of Mpdz impairs ependymal cell integrity leading to perinatal‐onset hydrocephalus in mice (2017) (41)
Increased levels of 2‐hydroxyglutarate in AML patients with IDH1‐R132H and IDH2‐R140Q mutations (2010) (41)
Protein kinase Cβ as a therapeutic target stabilizing blood–brain barrier disruption in experimental autoimmune encephalomyelitis (2013) (40)
Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1 (2019) (40)
Proximity ligation assay evaluates IDH1R132H presentation in gliomas. (2015) (40)
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients (2016) (39)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* (2018) (38)
Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma (2004) (38)
Investigation of germline GFRα-1 mutations in Hirschsprung disease (1999) (38)
Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. (2005) (38)
Analysis of the MEN1 gene in sporadic pituitary adenomas (1999) (38)
G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling (2021) (37)
BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma (2013) (37)
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. (2007) (36)
DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. (2019) (36)
A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era (2021) (36)
Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade (2016) (35)
A case history of glioma progression (1999) (35)
Expression of alpha B-crystallin in human brain tumors. (1993) (35)
YAP1-fusions in pediatric NF2-wildtype meningioma (2019) (35)
Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions (2019) (35)
Mutational analysis of INI1 in sporadic human brain tumors (2001) (35)
No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma (2004) (35)
Chromosome 22 tiling‐path array–CGH analysis identifies germ‐line‐ and tumor‐specific aberrations in patients with glioblastoma multiforme (2005) (34)
Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing (2018) (34)
Over-representation of PPARγ sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population (2000) (34)
Methylation analysis of the neurofibromatosis type 1 (NF1) promoter in peripheral nerve sheath tumours. (2004) (33)
Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). (2003) (33)
The miR‐139‐5p regulates proliferation of supratentorial paediatric low‐grade gliomas by targeting the PI3K/AKT/mTORC1 signalling (2018) (33)
Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors (2012) (33)
Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib (2018) (33)
Role of genomic instability in meningioma progression (1996) (32)
The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma (2018) (32)
Infratentorial IDH-mutant astrocytoma is a distinct subtype (2020) (32)
Oncogene complementation in fetal brain transplants. (1992) (32)
The 4q12 Amplicon in Malignant Peripheral Nerve Sheath Tumors: Consequences on Gene Expression and Implications for Sunitinib Treatment (2010) (32)
Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone (2016) (32)
Tuberous sclerosis-like lesions in epileptogenic human neocortex lack allelic loss at the TSC1 and TSC2 regions (1996) (31)
Clonality of multiple meningiomas. (1997) (31)
Ets‐1 is up‐regulated together with its target gene products matrix metalloproteinase‐2 and matrix metalloproteinase‐9 in atypical and anaplastic meningiomas (2006) (31)
Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas (2016) (31)
The Evolution of Our Understanding on Glioma (2008) (31)
Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. (2007) (30)
Location of N-methyl-N'-nitro-N-nitrosoguanidine-induced gastrointestinal tumors correlates with thiol distribution. (1983) (30)
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) (30)
Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis (2020) (30)
EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumors (2018) (30)
Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma (2018) (30)
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry (2018) (30)
Alterations of cell cycle regulators in gliomatosis cerebri (2005) (30)
Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma (1997) (30)
Cloning of a highly conserved human protein serine-threonine phosphatase gene from the glioma candidate region on chromosome 19q13.3. (1995) (30)
Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing (2016) (30)
Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants. (1997) (29)
Evaluation of a novel liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in an animal endovascular embolization model (2017) (29)
Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations (2019) (29)
A novel splice site associated polymorphism in the tuberous sclerosis 2 (TSC2) gene may predispose to the development of sporadic gangliogliomas. (1997) (29)
Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. (2016) (29)
Gene regulation by methylation. (2009) (29)
Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma (2018) (29)
Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase‐2 and MMP‐9 (2006) (28)
Intraoperative radiofrequency ablation of lung metastases and histologic evaluation. (2009) (28)
Astrocytic gliomas: characterization on a molecular genetic basis. (1994) (28)
Sensitivity of Malignant Peripheral Nerve Sheath Tumor Cells to TRAIL Is Augmented by Loss of NF1 through Modulation of MYC/MAD and Is Potentiated by Curcumin through Induction of ROS (2013) (27)
Identification of KIF11 as a Novel Target in Meningioma (2019) (27)
Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma (2009) (27)
A Polymerase Chain Reaction‐based Assay for the Rapid Detection of Gene Amplification in Human Tumors (1996) (27)
Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study (2018) (27)
Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma. (2020) (26)
Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells. (2004) (26)
Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome (2019) (26)
68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of Adenoid Cystic Carcinomas - imaging analysis and histological validation. (2021) (26)
DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas (2019) (26)
DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics (2019) (26)
Brain slice invasion model reveals genes differentially regulated in glioma invasion. (2005) (26)
MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma (2016) (26)
Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. (2013) (26)
Endometrial stromal sarcomas with BCOR‐rearrangement harbor MDM2 amplifications (2020) (25)
Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas (2003) (25)
The APC gene in Turcot's syndrome. (1995) (25)
Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents (2012) (25)
Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults (2019) (25)
An optimized protocol for mRNA quantification using nested competitive RT-PCR. (1997) (24)
Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma (2019) (24)
Mutant IDH sensitizes gliomas to endoplasmic reticulum stress and triggers apoptosis by MicroRNA183-mediated inhibition of Semaphorin 3E. (2019) (24)
Laser-assisted microdissection, techniques and applications in pathology (review). (2005) (24)
Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis (2016) (24)
Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. (2018) (23)
Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling (2018) (23)
Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients (2015) (23)
Granulomatous tissue response in germinoma, a diagnostic pitfall in endoscopic biopsy (2007) (23)
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine (2017) (23)
Epigenetically mediated downregulation of the differentiation‐promoting chaperon protein CRABP2 in astrocytic gliomas (2012) (23)
Molecular pathology of oligodendroglial tumors. (2009) (23)
Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. (2010) (22)
T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology (2020) (22)
Cross-species genomics reveals oncogenic dependencies in ZFTA/C11orf95 fusion-positive supratentorial ependymomas. (2021) (22)
Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors (2021) (22)
Somatic mitochondrial mutations in pilocytic astrocytoma. (2009) (22)
Mosaic trisomy of chromosome 1q in human brain tissue associates with unilateral polymicrogyria, very early-onset focal epilepsy, and severe developmental delay (2020) (21)
Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease (2001) (21)
Type and frequency of p53 mutations in tumors of the nervous system and its coverings. (1994) (20)
Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1 (2020) (20)
Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B (2021) (20)
Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma (2018) (20)
Brain metastases of gastro-oesophageal cancer: evaluation of molecules with relevance for targeted therapies. (2013) (20)
Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT (2019) (20)
LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild‐type glioblastoma patients (2016) (19)
Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. (2017) (19)
Diagnostic accuracy of DW MR imaging in the differentiation of chordomas and chondrosarcomas of the skull base: A 3.0-T MRI study of 105 cases. (2018) (19)
DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas (2018) (19)
Defective p53 antiangiogenic signaling in glioblastoma. (2010) (19)
PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum (2021) (19)
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. (2018) (18)
Nbn and Atm Cooperate in a Tissue and Developmental Stage-Specific Manner to Prevent Double Strand Breaks and Apoptosis in Developing Brain and Eye (2013) (17)
The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells. (2009) (17)
Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. (2020) (17)
Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma (2021) (17)
Prognostic relevance of miRNA-155 methylation in anaplastic glioma (2016) (17)
Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup (2021) (17)
Chromogenic in situ Hybridization is a Reliable Alternative to Fluorescence in situ Hybridization for Diagnostic Testing of 1p and 19q Loss in Paraffin‐Embedded Gliomas (2013) (17)
Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. (2021) (17)
Clinicopathologic and molecular features of intracranial desmoplastic small round cell tumors (2019) (16)
No Evidence for BRAF-V600E Mutations in Gastroeosophageal Tumors: Results From a High-throughput Analysis of 534 Cases Using a Mutation-specific Antibody (2013) (16)
Medulloblastoma Harbor Somatic Mitochondrial DNA Mutations in the D-loop Region (2010) (16)
The inhibitor of growth 1 (ING1) proteins suppress angiogenesis and differentially regulate angiopoietin expression in glioblastoma cells. (2009) (16)
Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas (2019) (16)
Prognostic impact of genetic alterations and methylation classes in meningioma (2022) (15)
Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity (2020) (15)
Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. (2019) (15)
Subgroup and subtype-specific outcomes in adult medulloblastoma (2021) (15)
Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas (2018) (15)
Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation (2011) (15)
Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors (2016) (15)
Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1 (2021) (15)
IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody (2010) (15)
Molecular genetic analysis as a tool for evaluating stereotactic biopsies of glioma specimens. (1999) (15)
Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation (2021) (14)
Clinical neuropathology practice news 2-2012: BRAF V600E testing (2012) (14)
Assessment of tumor cell invasion factors in gliomatosis cerebri (2005) (14)
Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. (2020) (14)
DNA methylation‐based profiling of bone and soft tissue tumours: a validation study of the ‘DKFZ Sarcoma Classifier’ (2021) (14)
Novel oncogene amplifications in tumors from a family with Li–Fraumeni syndrome (2009) (14)
Extra-small dual-lumen micro-balloon catheters can improve endovascular embolization: an experimental in vivo and in vitro study (2018) (14)
Investigation of germline GFR alpha-1 mutations in Hirschsprung disease. (1999) (14)
Association of allelic losses on human chromosomal arms 11q and 16q in sporadic breast cancer (1996) (13)
Kaposiform hemangioendothelioma and tufted angioma - (epi)genetic analysis including genome-wide methylation profiling. (2019) (13)
Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease (2019) (13)
Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma (2015) (13)
Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma (2019) (13)
No preferential loss of paternal 19q alleles in oligodendroglial tumors (2003) (12)
Oligosarcomas, IDH-mutant are distinct and aggressive (2021) (12)
A PRDX1‐p38α heterodimer amplifies MET‐driven invasion of IDH‐wildtype and IDH‐mutant gliomas (2018) (12)
Myxoid pleomorphic liposarcoma—a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma (2021) (12)
No evidence of hSNF5/INI1 point mutations in choroid plexus papilloma (2004) (12)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* (2019) (12)
Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival (2020) (11)
Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis (2021) (11)
Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years (2017) (11)
Mutational analysis of D2HGDH and L2HGDH in brain tumours without IDH1 or IDH2 mutations (2011) (10)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2018) (10)
Primary central nervous system sarcoma with DICER1 mutation—treatment results of a novel molecular entity in pediatric Peruvian patients (2021) (10)
Therapeutic implications of improved molecular diagnostics for rare CNS-embryonal tumor entities: results of an international, retrospective study. (2021) (10)
Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes (2020) (10)
Expression of Epstein-Barr virus membrane antigen gp350/220 in E. coli and in insect cells. (1992) (10)
DNA methylation-based classification of malformations of cortical development in the human brain (2021) (10)
First experiences with low-dose anti-angiogenic treatment in gliomatosis cerebri with signs of angiogenic activity. (2009) (9)
Analysis of the TSC2 gene in human medulloblastoma (2001) (9)
Localization of Blvr, biliverdin reductase, on mouse chromosome 2. (1989) (9)
Molecular diagnostics in drug‐resistant focal epilepsy define new disease entities (2021) (9)
Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry (2015) (9)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2019) (9)
Calcifying fibrous tumor and inflammatory myofibroblastic tumor are epigenetically related: A comparative genome-wide methylation study. (2019) (9)
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma (2022) (9)
Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis. (2017) (8)
TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities (2014) (8)
GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types (2021) (8)
Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas (2019) (8)
Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location‐dependent patterns of genetic and epigenetic alterations (2021) (8)
Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. (2017) (8)
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival (2022) (8)
Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making — A Selected Case Series (2018) (8)
Oligodendrogliomas: impact of molecular genetics on treatment. (2005) (8)
Primary CNS Alveolar Rhabdomyosarcoma: Importance of Epigenetic and Transcriptomic Assays for Accurate Diagnosis. (2019) (8)
Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation (2019) (8)
Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma (2020) (8)
Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? (2021) (7)
Assessment of Melanin Content and its Influence on Susceptibility Contrast in Melanoma Metastases (2019) (7)
PIK3CA mutations in oligodendroglial tumours (2006) (7)
Interorgan shift of nitrosamine metabolism by dietary ethanol. (1987) (7)
Differential concentration-dependent effects of prolonged norepinephrine infusion on intraparenchymal hemorrhage and cortical contusion in brain-injured rats. (2003) (7)
The anesthetist’s choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients (2020) (7)
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. (2022) (7)
Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies (2021) (7)
Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial. (2022) (7)
Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. (2017) (7)
Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23 (2021) (7)
Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. (2020) (7)
Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary. (2021) (7)
Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p (2018) (6)
Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation (2019) (6)
Transcription factor AP‐2 is expressed in human Schwann cell‐derived tumours (2006) (6)
The age of adult pilocytic astrocytoma cells (2021) (6)
Mutation specific antibodies: tool or dinosaur? (2012) (6)
Functional MHC class II is upregulated in neurofibromin-deficient Schwann cells. (2013) (6)
Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma (2021) (6)
Accurate calling of KIAA1549‐BRAF fusions from DNA of human brain tumours using methylation array‐based copy number and gene panel sequencing data (2020) (6)
Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas (1999) (6)
Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines (2020) (6)
mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation (2017) (5)
High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. (2019) (5)
Intracranial mesenchymal tumors with FET‐CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas (2021) (5)
Integrated molecular analysis of adult Sonic Hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. (2021) (5)
Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study (2021) (5)
Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1 (2019) (5)
DNA methylation-based classification of sinonasal tumors (2022) (5)
Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study (2022) (5)
Deep Neural Network for Differentiation of Brain Tumor Tissue Displayed by Confocal Laser Endomicroscopy (2021) (5)
T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas (2021) (5)
Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. (2018) (5)
Genetic and epigenetic characterization of posterior pituitary tumors (2021) (5)
Chromosomal imbalances and NF2 mutational analysis in a series of 10 spinal nerve sheath myxomas (2007) (5)
Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion (2021) (4)
MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT (2020) (4)
Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report (2020) (4)
Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype (2021) (4)
An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data (2020) (4)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2019) (4)
Analysis of a surgical series of 21 cerebral radiation necroses. (2020) (4)
Decreased expression of the active subunit of the cystine/glutamate antiporter xCT is associated with loss of heterozygosity of 1p in oligodendroglial tumours WHO grade II (2009) (4)
Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death (2013) (4)
Occurrence of a spinal anaplastic pilocytic astrocytoma and a supratentorial PNET in an adolescent. (2007) (4)
Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohorts (2022) (4)
Epidermal Nbn deletion causes premature hair loss and a phenotype resembling psoriasiform dermatitis (2016) (4)
Correction: Nbn and Atm Cooperate in a Tissue and Developmental Stage-Specific Manner to Prevent Double Strand Breaks and Apoptosis in Developing Brain and Eye (2013) (4)
RINT1 functions as a multitasking protein at the crossroads between genomic stability, ER homeostasis, and autophagy (2016) (4)
Spindle Cell Sarcoma of the Uterine Corpus With Adipose Metaplasia: Expanding the Morphologic Spectrum of Neoplasms With MEIS1-NCOA2 Gene Fusion. (2021) (4)
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors (2022) (4)
An activating germline IDH1 variant associated with a tumor entity characterized by unilateral and bilateral chondrosarcoma of the mastoid (2020) (4)
Endometrial Stromal Sarcomas With BCOR Internal Tandem Duplication and Variant BCOR/BCORL1 Rearrangements Resemble High-grade Endometrial Stromal Sarcomas With Recurrent CDK4 Pathway Alterations and MDM2 Amplifications (2022) (3)
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2022) (3)
Ectopic intracranial retinoblastoma in a 3.5‐month‐old infant without eye involvement and without evidence of heritability (2019) (3)
Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG (2013) (3)
Interdisciplinary approach allows minimally invasive, nerve-sparing removal of retroperitoneal peripheral nerve sheath tumors (2020) (3)
AAMP is a binding partner of costimulatory human B7-H3 (2022) (3)
DNA methylation profiling discriminates between malignant pleural mesothelioma and neoplastic or reactive histological mimics. (2021) (3)
Mapping of the chromosome 19 q‐arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers (2000) (3)
Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02 (2019) (3)
OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas (2018) (3)
BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential. (2018) (3)
Influence of expression of EGFR and PTEN on outcome in patients with primary glioblastoma treated with standard radiochemotherapy and cetuximab: Interim analysis from the GERT-Protocol. (2016) (3)
Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs (2018) (3)
Cellular context determines DNA methylation profiles in SWI/SNF‐deficient cancers of the gynecologic tract (2022) (3)
Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. (2022) (3)
Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma (2020) (3)
RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas (2019) (3)
Clinical implementation of integrated molecular‐morphologic risk prediction for meningioma (2022) (3)
Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry. (2022) (2)
Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019. (2020) (2)
Analysis of CIC‐associated CpG island methylation in oligoastrocytoma (2013) (2)
Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification (2022) (2)
Germline SDHB‐inactivating mutation in gastric spindle cell sarcoma (2020) (2)
Bone marrow biopsies of patients with hematopoietic and lymphoid disorders - epidemiology, chromosomal aberrations and molecular pathology. (2012) (2)
Secondary anaplastic astrocytoma developing in a young adult with autoimmune lymphoproliferative syndrome (ALPS). (2011) (2)
Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary (2022) (2)
Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma (2015) (2)
Opinion & Special Article: Glioma Classification (2022) (2)
Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes (2021) (2)
[Solid craniopharyngioma in the 3rd ventricle--differential diagnostic aspects]. (1998) (2)
Correction: A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1 (2013) (2)
Epigenetic profiling reveals a subset of pediatric-type glioneuronal tumors characterized by oncogenic gene fusions involving several targetable kinases (2022) (2)
Rapid-CNS2: Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study (2021) (2)
Clinical Significance of Molecular Diagnosis of Pilocytic Astrocytoma: A Case Report (2019) (2)
Molecular characterisation of sporadic endolymphatic sac tumours and comparison to von Hippel–Lindau disease‐related tumours (2021) (2)
Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre (2019) (2)
Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles (2016) (2)
[Induction of primitive neuroectodermal tumors by oncogene complementation]. (1990) (2)
Predictive value of IDH1 mutation assessed by immunohistochemistry and DNA sequencing in WHO grade 3 oligodendrogliomas. (2011) (2)
Comparison of transcriptome profiles between medulloblastoma primary and recurrent tumors uncovers novel variance effects in relapses (2023) (2)
DNA-Methylation Analysis as a Tool for Thymoma Classification (2022) (1)
Paul Kleihues (1936-2022), neuropathology innovator and entrepreneur. (2022) (1)
Intrathecal activation of CD8+ memory T cells in IgG4‐related disease of the brain parenchyma (2021) (1)
Methylation classifiers: Brain tumors, sarcomas, and what's next (2022) (1)
New developments and controversies in the neuropathology of malignant gliomas. (1999) (1)
Anaplastic ganglioglioma—A diagnosis comprising several distinct tumour types (2022) (1)
The molecular evolution of glioblastoma treated by gross total resection alone. (2020) (1)
High-Grade Endometrial Stromal Sarcomas With YWHAE::NUTM2 Gene Fusion Exhibit Recurrent CDKN2A Alterations and Absence of p16 Staining is a Poor Prognostic Marker. (2023) (1)
Analysis of a polymorphism in the tuberous sclerosis (TSC2) gene does not predispose to schizophrenia (1998) (1)
P07.04 Rapid-CNS2: Rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof of concept study (2021) (1)
Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression (2022) (1)
BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. (2022) (1)
Single-cell DNA sequencing reveals order of mutational acquisition in TRAF7/AKT1 and TRAF7/KLF4 mutant meningiomas (2022) (1)
Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology (2023) (1)
NIMG-30. PREOPERATIVE PREDICTORS OF MALIGNANCY IN NON-ENHANCING GLIOMA IN THE ERA OF MOLECULAR CLASSIFICATION (2018) (1)
ATIM-35. VXM01 PHASE I STUDY IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA – FINAL RESULTS (2018) (1)
OTHR-41. Amplification of the PLAG family genes – PLAGL1 and PLAGL2 – is a key feature of a novel embryonal CNS tumor type (2022) (1)
Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. (2020) (1)
Actively personalized vaccination trial for newly diagnosed glioblastoma (2018) (1)
Pathology (1916) (0)
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells (2022) (0)
HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. (2022) (0)
Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal cholangiocarcinogenesis (2021) (0)
PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORS—THE MNP 2.0 STUDY (2020) (0)
MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY? (2020) (0)
Diagnostic potential of extracellular vesicles in meningioma patients. (2022) (0)
LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients (2022) (0)
Spatial probabilistic mapping of metabolite ensembles in mass spectrometry imaging (2021) (0)
Concurrent gliomas in patients with multiple sclerosis (2022) (0)
PATH-23. OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE (2021) (0)
Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT (2019) (0)
PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS (2020) (0)
DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients (2022) (0)
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (2018) (0)
Distribution of GOPC:ROS1 and other ROS1 fusions in glioma types (2021) (0)
MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome (2022) (0)
PATH-46. DIAGNOSTIC IMPACT OF THE CNS TUMOR METHYLATION PROFILING IN A NEUROPATHOLOGY CONSULT PRACTICE (2021) (0)
PATH-34. MOLECULAR AND CLINICAL HETEROGENEITY WITHIN SPINAL EPENDYMOMAS (2021) (0)
LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. (2023) (0)
MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE (2018) (0)
Identification of epigenetically regulated genes distinguishing intracranial from extracranial melanoma metastases. (2023) (0)
Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes. (2023) (0)
CIC protein instability contributes to tumorigenesis in glioblastoma (2019) (0)
Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data (2020) (0)
C.07 Predicting individualized risk of recurrence: development and validation of a DNA-methylation based nomogram in meningioma (2019) (0)
Impact of post-surgical freezing delay on brain tumor metabolomics (2019) (0)
Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study (2019) (0)
PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED (2021) (0)
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas (2020) (0)
DNA hybridization subtraction: differences detected between BALB/cAnPt and BALB/cJax at the DNA level. (1985) (0)
A RsaI polymorphism in the ERCC2 locus. (1992) (0)
Report of a Novel Case of Anaplastic Olfactory Groove Meningioma and Its Methylation Subtype. (2017) (0)
EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY (2021) (0)
Detection of IDH1 mutations in a series of 91 oligodendrogliomas: Comparison of immunohistochemistry, DNA sequencing, and allele-specific PCR. (2011) (0)
D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma (2014) (0)
KS05.6.A Oral DNA vaccination targeting VEGFR2 combined with the anti-PD-L1 antibody avelumab in patients with progressive glioblastoma - final results. NCT03750071 (2022) (0)
EPEN-27. Epigenetic dissection of spinal ependymomas (SP-EPN) separates tumors with and withoutNF2 mutation (2022) (0)
Corrigendum to 'Molecular diagnostics enables detection of actionable targets: the Pediatric Targeted Therapy 2.0 registry' [Eur J Cancer 180 (2023) 71-84]. (2023) (0)
Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry (2018) (0)
DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma (2022) (0)
G3BP1 tethers the TSC complex to lysosomes and suppresses mTORC1 in the absence of stress granules (2020) (0)
Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort (2023) (0)
Risk Estimation in Non-Enhancing Glioma: Introducing a Clinical Score (2023) (0)
P12.12.A Resolving the cellular architecture of infiltration zones in glioblastoma (2022) (0)
LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma (2022) (0)
MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN) (2020) (0)
MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy – Results of the MET-HIT2000-BIS4 trial (2022) (0)
Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) (0)
PATH-46. COMPUTATIONAL HISTOPATHOLOGY INFORMED RAPID TARGETED NANOPORE SEQUENCING ENABLES AFFORDABLE NEXT DAY REPORTING OF COMPREHENSIVE MOLECULAR MARKERS FOR CNS TUMOUR DIAGNOSTICS (2022) (0)
IN INDEPENDENT OFFERING A UNIQUE TREATMENT PARADIGM FOR P08.48 COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA (0)
Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation (2021) (0)
Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery (2017) (0)
Correction to: Amplification of the PLAG-family genes—PLAGL1 and PLAGL2—is a key feature of the novel tumor type CNS embryonal tumor with PLAGL amplification (2023) (0)
Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas (2017) (0)
PFKFB4 interacts with FBXO28 to promote HIF-1α signaling in glioblastoma (2022) (0)
SOCIETY NEWS (2006) (0)
Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas (2019) (0)
Genomic characterization of DICER1-associated neoplasms uncovers molecular classes (2023) (0)
RADT-34. ANALYSIS OF A METHYLATION CLASS-GUIDED RADIOTHERAPY IN MENINGIOMA PATIENTS - AND THE PROSPECTIVE PHASE II MARCIE TRIAL WITH CARBON-ION BOOST RADIOTHERAPY (2022) (0)
Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS <12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY (2020) (0)
BIOM-39. METHYLATION AND MUTATION PROFILES IN MENINGIOMA CELL-DERIVED EXTRACELLULAR VESICLE DNA REFLECT EPIGENETIC AND GENOMIC ALTERATIONS IN ORIGINAL TUMORS (2021) (0)
QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL (2020) (0)
Scientific correspondence (2011) (0)
EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM (2021) (0)
BIOM-35. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY (2021) (0)
The molecular landscape of ETMR at diagnosis and relapse (2019) (0)
Lower-grade glioma in elderly patients: treatment and outcomes in a molecularly characterized contemporary cohort (2022) (0)
PATH-04. AN ENHANCED AI-DRIVEN PLATFORM FOR PRECISION MOLECULAR BRAIN TUMOR DIANOSTICS (2020) (0)
[Progression-associated gene regions in astrocytomas: a candidate locus on chromosome 19q]. (1994) (0)
Clinical outcome following surgical resection and radiotherapy in adult patients with pleomorphic xanthoastrocytoma as defined by DNA methylation profiling (2023) (0)
Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival (2022) (0)
MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS (2020) (0)
EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS (2021) (0)
PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study (2022) (0)
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma (2019) (0)
Correction to: DNA methylation-based reclassification of olfactory neuroblastoma (2018) (0)
Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients (2016) (0)
Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions (2023) (0)
LGG-33. ISOMORPHIC DIFFUSE GLIOMA HAS RECURRENT GENE FUSIONS OF MYBL1 OR MYB AND CAN BE DISTINGUISHED FROM OTHER MYB/MYBL1 ALTERED GLIOMAS BASED ON A DISTINCT MORPHOLOGY AND DNA METHYLATION PROFILE (2020) (0)
LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma (2022) (0)
Adult cerebellar glioblastoma categorized into a pediatric methylation class with a unique radiological and histological appearance: illustrative case (2022) (0)
NCOG-25. REVISITING THE PIGNATTI RISK SCORE IN LOW-GRADE GLIOMA PATIENTS IN THE MOLECULAR ERA (2021) (0)
RARE-42. PRIMARY INTRACRANIAL SARCOMA WITH DICER1-MUTATION - TREATMENT RESULTS OF A NEW MOLECULAR ENTITY (2020) (0)
OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology (2022) (0)
EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA (2020) (0)
Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature (2023) (0)
MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS (2020) (0)
Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies (2022) (0)
Reprogramming M2-polarized patient-derived glioblastoma associated microglia/macrophages via CSF1R inhibition (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Andreas von Deimling?

Andreas von Deimling is affiliated with the following schools:

Technical University of Munich
Heidelberg University

Andreas von Deimling's Academic­Influence.com Rankings

Why Is Andreas von Deimling Influential?

Andreas von Deimling's Published Works

Published Works

What Schools Are Affiliated With Andreas von Deimling?

Andreas von Deimling's AcademicInfluence.com Rankings